Agenovir Lands $10,600,000 Series A Financing Round

  • Feed Type
  • Date
    5/18/2016
  • Company Name
    Agenovir
  • Mailing Address
    329 Oyster Point Blvd. 3rd Floor South San Francisco, CA 94080 USA
  • Company Description
    Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with or caused by latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited or non-existent.
  • Website
    http://www.agenovir.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,600,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    With this financing led by top tier venture, corporate and individual investors, we expect to build an exceptional leadership team and accelerate our research and development programs to treat diseases associated or caused by latent or persistent viral reservoirs.
  • M&A Terms
  • Venture Investor
    Data Collective
  • Venture Investor
    Celgene
  • Venture Investor
    Lightspeed Venture Partners
  • Venture Investor
    Undisclosed

Trending on Xconomy